MA29368B1 - Formes posologiques resistant a l'extraction alcoolique - Google Patents

Formes posologiques resistant a l'extraction alcoolique

Info

Publication number
MA29368B1
MA29368B1 MA30117A MA30117A MA29368B1 MA 29368 B1 MA29368 B1 MA 29368B1 MA 30117 A MA30117 A MA 30117A MA 30117 A MA30117 A MA 30117A MA 29368 B1 MA29368 B1 MA 29368B1
Authority
MA
Morocco
Prior art keywords
dosage forms
alcohol extraction
forms resistant
resistant
opioid
Prior art date
Application number
MA30117A
Other languages
English (en)
Inventor
Richard O Mannion
William H Mckenna
Edward P O'donnell
Helen Kathleen Danagher
Geoffrey Gerard Hayes
Hassan Mohammad
Derek Allan Prater
Harjit Tamber
Malcolm Walden
Steve Whitelock
Wolfgang Fleischer
Udo Hahn
Christof Spitzley
Christian Leuner
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2005/050014 external-priority patent/WO2005079760A1/fr
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MA29368B1 publication Critical patent/MA29368B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/02—Making granules by dividing preformed material
    • B29B9/06—Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B29K2033/04—Polymers of esters
    • B29K2033/12—Polymers of methacrylic acid esters, e.g. PMMA, i.e. polymethylmethacrylate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0085—Copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mechanical Engineering (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'INVENTION CONCERNE DES FORMULATIONS À LIBÉRATION CONTRÔLÉE D'OPIOÏDE RÉSISTANT À L'EXTRACTION ALCOOLIQUE DE L'OPIOÏDE.
MA30117A 2005-01-28 2007-07-27 Formes posologiques resistant a l'extraction alcoolique MA29368B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0501638.1A GB0501638D0 (en) 2005-01-28 2005-01-28 Particulates
PCT/GB2005/050014 WO2005079760A1 (fr) 2004-02-12 2005-02-11 Matieres particulaires
US67050605P 2005-04-12 2005-04-12
US73033905P 2005-10-26 2005-10-26

Publications (1)

Publication Number Publication Date
MA29368B1 true MA29368B1 (fr) 2008-04-01

Family

ID=34259727

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30117A MA29368B1 (fr) 2005-01-28 2007-07-27 Formes posologiques resistant a l'extraction alcoolique

Country Status (11)

Country Link
EP (3) EP3228308A1 (fr)
JP (2) JP5704789B2 (fr)
CN (1) CN101132772B (fr)
AP (1) AP2274A (fr)
EA (1) EA015615B1 (fr)
GB (1) GB0501638D0 (fr)
IL (1) IL184858A (fr)
MA (1) MA29368B1 (fr)
NZ (2) NZ560669A (fr)
TN (1) TNSN07293A1 (fr)
ZA (1) ZA200705913B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US9757343B2 (en) * 2008-09-24 2017-09-12 Evonik Röhm Gmbh PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
WO2010105673A1 (fr) * 2009-03-18 2010-09-23 Evonik Röhm Gmbh Composition pharmaceutique à libération controlée avec résistance contre l'influence d'éthanol au moyen d'un enrobage comportant un mélange de polymères et excipients
US9730899B2 (en) * 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
KR20130030260A (ko) * 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 히드로모르폰 및 날록손을 포함하는 제약 조성물
NZ603173A (en) * 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
WO2011141490A1 (fr) * 2010-05-10 2011-11-17 Euro-Celtique S.A. Combinaison de granules chargés de principe actif et de principes actifs supplémentaires
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
WO2012166474A1 (fr) * 2011-06-01 2012-12-06 Fmc Corporation Formes posologiques solides à libération contrôlée
BR112014009033A2 (pt) * 2011-10-18 2017-10-17 Purdue Pharma Lp formulações de polímero acrílico
DK2838512T3 (en) * 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
CA2795324C (fr) * 2012-11-09 2015-07-14 Purdue Pharma Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
CN105120846B (zh) * 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US11806433B2 (en) 2017-11-01 2023-11-07 Edgemont Pharmaceuticals, LLC Trust Alcohol-resistant oral pharmaceutical compositions of lorazepam

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
WO1999001111A1 (fr) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Formulations de tramadol stabilisees a liberation prolongee
DE19901085C2 (de) * 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
WO2003004009A1 (fr) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Formulation a compression directe de medicaments faiblement compressibles tels que le chlorhydrate de metformine
KR20040060917A (ko) * 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
CA2455420A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions et procedes servant a empecher la surconsommation d'opioides
CA2478515C (fr) * 2002-04-05 2010-09-28 Purdue Pharma Preparation pharmaceutique contenant oxycodone et naloxone
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
CA2499994C (fr) * 2002-09-23 2012-07-10 Verion, Inc. Compositions pharmaceutiques n'induisant pas l'abus
ATE482695T1 (de) * 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
EP1585501A4 (fr) * 2003-01-23 2007-04-25 Amorepacific Corp Preparations a liberation prolongee et procede de production de ces preparations
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates

Also Published As

Publication number Publication date
AP2007004099A0 (en) 2007-08-31
CN101132772A (zh) 2008-02-27
NZ560669A (en) 2012-09-28
EA200701595A1 (ru) 2008-02-28
NZ590772A (en) 2012-05-25
CN101132772B (zh) 2012-05-09
EA015615B1 (ru) 2011-10-31
AP2274A (en) 2011-08-19
EP2319499A1 (fr) 2011-05-11
JP5704789B2 (ja) 2015-04-22
EP2289491A1 (fr) 2011-03-02
IL184858A (en) 2016-03-31
GB0501638D0 (en) 2005-03-02
EP3228308A1 (fr) 2017-10-11
TNSN07293A1 (fr) 2008-12-31
JP2013100306A (ja) 2013-05-23
IL184858A0 (en) 2007-12-03
JP2008528534A (ja) 2008-07-31
ZA200705913B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
TNSN07293A1 (fr) Formes posologiques resistant a l'extraction alcoolique
BRPI0606339A2 (pt) formas farmacêuticas resistentes a álcool
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
DK1888031T3 (da) GLP-1-analogformuleringer
EP2095275A4 (fr) Recherche d'un événement
BRPI0810646A2 (pt) " compostos farmacêuticos ".
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
DK1879623T3 (da) Genterapi til rygmarvssygdomme
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0509184A (pt) composições farmacêuticas
EP2032833A4 (fr) Isolant de bougie d'allumage
SI1940817T1 (sl) Holinergični ojačevalci z izboljšano hematoencefalno barierno propustnostjo za zdravljenje bolezni, ki spremljajo upad kognitivnih sposobnosti
ZA200702418B (en) Taste-masking Pharmaceutical compositions
EP1991691A4 (fr) Détection des facteurs de pathogénicité de l'anthrax
EP2019593A4 (fr) Promédicaments d'alcool tertiaire
BRPI0607474A2 (pt) vacinação enriquecida com glicosido-alquila
EA200900261A1 (ru) Применение эсцина
ZA200708699B (en) Pharmaceutical formulations amyloid inhibiting compounds
ECSP066564A (es) Formulaciones de tableta de liberación extendida de venlafaxina
ITTO20060879A1 (it) Unita' per la costruzione di solette a cialda.
ATE537816T1 (de) Leflunomid enthaltende pharmazeutische zusammensetzungen
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
EP2072498A4 (fr) Dérivé d'acide n-phényloxamidique
EP2319145A4 (fr) Bougie d'allumage de type à extension
HK1102110A (en) Alcohol resistant dosage forms